Cholecalciferol Intervention to Prevent Respiratory Infections Study: a Double-blind Randomised Controlled Trial to Evaluate the Efficacy of 20,000 IU/wk Cholecalciferol in Reducing Respiratory Tract Infection in a Cohort of Healthy Young Adults.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Colecalciferol (Primary)
- Indications Respiratory tract infections
- Focus Therapeutic Use
- Acronyms CIPRIS
- 19 Oct 2012 Biomarkers information updated
- 18 Oct 2012 New source identified and integrated (Australian New Zealand Clinical Trials Registry, ACTRN12612000054819).
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.